Finch Therapeutics Group (FNCH) Stock Forecast, Price Target & Predictions
FNCH Stock Forecast
Finch Therapeutics Group stock forecast is as follows: an average price target of $15.30K (represents a 133992.90% upside from FNCH’s last price of $11.41) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
FNCH Price Target
The average price target for Finch Therapeutics Group (FNCH) is $15.30K based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $15.30K to $15.30K. This represents a potential 133992.90% upside from FNCH's last price of $11.41.
FNCH Analyst Ratings
According to 1 Wall Street analysts, Finch Therapeutics Group's rating consensus is 'Buy'. The analyst rating breakdown for FNCH stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Finch Therapeutics Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 05, 2022 | Roger Song | Jefferies | - | - | 245.53% | 133992.90% |
The latest Finch Therapeutics Group stock forecast, released on Apr 05, 2022 by Roger Song from Jefferies, set a price target of $15.30K, which represents a 245.53% increase from the stock price at the time of the forecast ($4.43K), and a 133992.90% increase from FNCH last price ($11.41).
Finch Therapeutics Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $11.41 | $11.41 | $11.41 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Finch Therapeutics Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Finch Therapeutics Group's last price of $11.41. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 05, 2022 | Jefferies | Buy | Buy | Hold |
Finch Therapeutics Group's last stock rating was published by Jefferies on Apr 05, 2022. The company gave FNCH a "Buy" rating, the same as its previous rate.
Finch Therapeutics Group Financial Forecast
Finch Therapeutics Group Revenue Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | $8.00K | $138.00K | $361.00K | $806.00K | $3.55M |
| Avg Forecast | - | - | $400.00K | $750.00K | $650.00K | $5.00M | $3.60M |
| High Forecast | - | - | $400.00K | $750.00K | $650.00K | $5.00M | $3.60M |
| Low Forecast | - | - | $400.00K | $750.00K | $650.00K | $5.00M | $3.60M |
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | 0.02% | 0.18% | 0.56% | 0.16% | 0.99% |
Finch Therapeutics Group's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. FNCH's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $8.00K (Dec 22).
Finch Therapeutics Group EBITDA Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | $-27.27M | $-573.00K | $-19.45M | $-18.38M | $-13.61M |
| Avg Forecast | - | - | $-400.00K | $-750.00K | $-650.00K | $-5.00M | $-26.55M |
| High Forecast | - | - | $-400.00K | $-750.00K | $-650.00K | $-5.00M | $-21.24M |
| Low Forecast | - | - | $-400.00K | $-750.00K | $-650.00K | $-5.00M | $-31.85M |
| Surprise % | - | - | 68.17% | 0.76% | 29.93% | 3.68% | 0.51% |
undefined analysts predict FNCH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Finch Therapeutics Group's previous annual EBITDA (undefined) of $NaN.
Finch Therapeutics Group Net Income Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | $-26.32M | $-40.11M | $-22.77M | $-19.05M | $-13.98M |
| Avg Forecast | $2.48M | $2.16M | $-15.90M | $-20.23M | $-20.71M | $-15.42M | $-27.26M |
| High Forecast | $2.48M | $2.16M | $-15.90M | $-20.23M | $-20.71M | $-15.42M | $-21.81M |
| Low Forecast | $2.48M | $2.16M | $-15.90M | $-20.23M | $-20.71M | $-15.42M | $-32.72M |
| Surprise % | - | - | 1.66% | 1.98% | 1.10% | 1.24% | 0.51% |
Finch Therapeutics Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FNCH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Finch Therapeutics Group SG&A Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | $10.94M | $9.58M | $8.16M | $5.07M | $4.55M |
| Avg Forecast | - | - | $23.95M | $44.91M | $38.93M | $299.43M | $215.59M |
| High Forecast | - | - | $23.95M | $44.91M | $38.93M | $299.43M | $215.59M |
| Low Forecast | - | - | $23.95M | $44.91M | $38.93M | $299.43M | $215.59M |
| Surprise % | - | - | 0.46% | 0.21% | 0.21% | 0.02% | 0.02% |
Finch Therapeutics Group's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to FNCH last annual SG&A of $10.94M (Dec 22).
Finch Therapeutics Group EPS Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | $-0.55 | $-0.84 | $-0.48 | $-0.40 | $-1.00 |
| Avg Forecast | $1.54 | $1.34 | $-9.90 | $-12.60 | $-12.90 | $-9.60 | $-30.00 |
| High Forecast | $1.54 | $1.34 | $-9.90 | $-12.60 | $-12.90 | $-9.60 | $-30.00 |
| Low Forecast | $1.54 | $1.34 | $-9.90 | $-12.60 | $-12.90 | $-9.60 | $-30.00 |
| Surprise % | - | - | 0.06% | 0.07% | 0.04% | 0.04% | 0.03% |
According to undefined Wall Street analysts, Finch Therapeutics Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FNCH previous annual EPS of $NaN (undefined).
Finch Therapeutics Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FNCH | Finch Therapeutics Group | - | - | 133992.90% | Buy |
| KPRX | Kiora Pharmaceuticals | - | - | 3525.38% | Buy |
| BWV | Onconetix | - | - | 2122.22% | Buy |
| XLO | Xilio Therapeutics | - | - | 660.87% | Buy |
| HOWL | Werewolf Therapeutics | - | - | 574.16% | Buy |
| LGVN | Longeveron | - | - | 434.76% | Buy |
| CCCC | C4 Therapeutics | - | - | 236.66% | Buy |
| STOK | Stoke Therapeutics | - | - | 171.52% | Buy |
| ELYM | Eliem Therapeutics | - | - | 154.40% | Buy |
| CELC | Celcuity | - | - | 147.45% | Buy |
| DSGN | Design Therapeutics | - | - | 73.61% | Buy |
| EWTX | Edgewise Therapeutics | - | - | 40.71% | Buy |
| IKNA | Ikena Oncology | - | - | -23.12% | Buy |